Stock Events

Stock Events

CohBar 

$0.41
21
-$0.04-8.89% Thursday 20:11

Statistics

Day High
0.41
Day Low
0.41
52W High
1.01
52W Low
0
Volume
172
Avg. Volume
3,044
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

22NovExpected
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Q3 2024
-1.49
-1.24
-1
-0.75
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2017
2018
2019
2020
2021
2022
0Revenue
-12.18MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CWBR. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Senseonics
SENS
Mkt Cap288.22M
Senseonics Holdings focuses on diabetes management solutions, competing indirectly with CohBar's metabolic disease targets.
Conmed
CNMD
Mkt Cap1.08B
ConMed Corporation, while more broadly focused on medical devices, competes in the space of treatments for conditions that CohBar's therapies may also address.
Lineage Cell Therapeutics
LCTX
Mkt Cap391.07M
Lineage Cell Therapeutics works on regenerative therapies for diseases of aging, which overlaps with CohBar's therapeutic development goals.
Geron
GERN
Mkt Cap1.06B
Geron Corporation's focus on telomerase inhibitors for cancer and aging diseases places it in competition with CohBar's approach to aging and metabolic diseases.
Sarepta Therapeutics
SRPT
Mkt Cap2.44B
Sarepta Therapeutics, known for its work in genetic modulation and rare diseases, competes in the broader market for innovative treatments in areas that could intersect with CohBar's interests.
vTv Therapeutics
VTVT
Mkt Cap162.15M
vTv Therapeutics focuses on clinical-stage drug development for diabetes and Alzheimer's, competing in the metabolic disease and aging space relevant to CohBar.

About

CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes, acute respiratory distress syndrome, cancer, and cardiovascular diseases, such as Alzheimer's disease. Its lead clinical candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of NASH and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases; and CB5064 analogs for COVID-19 associated ARDS. CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California.
Show more...
CEO
Dr. Pinchas Cohen Dean, M.D., Ph.D.
Employees
9
Country
US
ISIN
US19249J1097

Listings

0 Comments

Share your thoughts

FAQ

What is CohBar stock price today?▼
The current price of CWBR is $0.41 USD — it has decreased by -8.89% in the past 24 hours. Watch CohBar stock price performance more closely on the chart.
What is CohBar stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange CohBar stocks are traded under the ticker CWBR.
What is CohBar revenue for the last year?▼
CohBar revenue for the last year amounts to 0 USD.
What is CohBar net income for the last year?▼
CWBR net income for the last year is -12.18M USD.
How many employees does CohBar have?▼
As of April 11, 2026, the company has 9 employees.
In which sector is CohBar located?▼
CohBar operates in the Health Care sector.
When did CohBar complete a stock split?▼
The last stock split for CohBar was on September 23, 2022 with a ratio of 1:30.
Where is CohBar headquartered?▼
CohBar is headquartered in Menlo Park, US.